ENDOTARGET third biannual consortium meeting in Naples
ENDOTARGET consoritum gathered in Naples for the third biannual consortium meeting
In the scenic city of Naples, located in Bella Italia and at the foot of Mount Vesuvius, the ENDOTARGET consortium met for its third biannual meeting on the 11th and 12th of April, 2024. Hosted at the University of Campania, the meeting was an important moment in our shared journey to unravel the mechanisms of rheumatic diseases. With passion and determination, our dedicated partners threw themselves into activities to drive the project forward. In lively discussions and brainstorming, ideas were exchanged and the next steps for our future breakthroughs were determined.
Warmly welcomed by our coordinator, Kari Eklund, and our host, Francesco Ciccia, on the morning of the first day of the meeting, the consortium wasted no time in diving into project discussions. Ethical topics took centre stage, with lively debates and interactive sessions leading us to a shared understanding of our responsibilities. Later in the day, we delved into dissemination, communication and exploitation, including a short status presentation and an interactive exploitation workshop, exploring ways to share our results with the world and maximise the impact of our research. The working day was concluded with a project management session, focusing on the upcoming reporting. Of course, no Italian gathering would be complete without indulging in the exquisite flavours of the local cuisine. Bonds were strengthened and memories were made over a sumptuous dinner of delicious seafood.
Day two focused on our scientific endeavours, with presentations showcasing the remarkable progress made across our work packages. In the afternoon, the Clinical Board meeting took centre stage, where strategic planning and collaborations were intensified.
At the end of the meeting, participants left with a renewed sense of purpose and commitment to the ENDOTARGET mission. With these updates, the ENDOTARGET project continues to make significant strides in advancing our understanding of rheumatic diseases and paving the way for improved diagnostics, treatments, and outcomes.
For more information have a look at our press release, also available in different languages: 3rd ENDOTARGET Press Release
